Ferreira, I.J., Sousa, F., Vasco, E.M., de Amaral Areia, A.L., Moura, J.P., Carda, J., Ribeiro, L. (2018) Severe Immune Thrombocytopenia in Pregnancy Treated with Eltrombopag—A Case Report. Journal of Gynecology Obstetrics and Human Reproduction, 47, 405-408.
https://doi.org/10.1016/j.jogoh.2018.06.010

has been cited by the following article:

• TITLE: Eltrombopag Managed Severe Immune Thrombocytopenic Purpura in Pregnancy: A Case Report, Latifa Hospital, DHA, Dubai, UAE

  AUTHORS: Komal Sundeep Hazari, Atif Bashir E. Fazari, Taghrid Gergawi, Hasan Mohamed A. Aal-Yaseen, Nighat Aftab

  KEYWORDS: Immune Thrombocytopenic Purpura, Eltrombopag, Pregnancy

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.9 No.7, July 18, 2019

  ABSTRACT: Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder, defined by a platelet count of less than 100 × 109/L, secondary to impaired production and immune destruction of platelets. Bleeding tendency is the main presentation of this condition. Clinical symptoms and investigations will confirm the diagnosis. Steroid is the first line of treatment. Although Rituximab and Thrombopoietin receptor agonists are useful second line agents in non-pregnant adults, the data about their role in pregnancy are still limited. We present the case of a 30 year old primigravida, who was a known case of chronic ITP since childhood; the course of her disease was fluctuating, for which oral steroids were used accordingly. She presented with gum bleeding and petechial rash with very low platelets count. She was sponsored by the Patient Support Program and was given Eltrombopag during the third trimester. She responded well to Eltrombopag with no noticeable side effects, neither to the mother nor to the baby so far. Eltrombopag has been assigned Category C by the Federal Drugs Agency (FDA) nevertheless there are no well controlled data in the literature about its role in pregnancy.